DelveInsight’s “Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Molybdenum Cofactor Deficiency Type-A (MoCoD-A): An Overview
Molybdenum cofactor deficiency (MoCoD-A) is a severe autosomal recessive inborn error of metabolism characterized by the neonatal presentation of intractable seizures, feeding difficulties, developmental delays, microcephaly with brain atrophy, and coarse facial features.
MoCoD type A is a rapidly progressive genetic disease. It cannot be outgrown. It has a high infant mortality rate. Most patients die in early childhood from infections. An early diagnosis is critical to any chance of improving outcomes.
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Key Facts
-
Molybdenum cofactor deficiency is an ultra-rare severe autosomal recessive neonatal metabolic disease that causes seizures and death or severe brain damage. Various publications state that MoCoD is estimated to occur in 1 in 100,000 to 200,000 newborns worldwide, and more than 100 cases have been reported in the medical Literature.
-
In 2021, the EU-5 accounted for 92 prevalent cases of Molybdenum cofactor deficiency, which are expected to increase in the forecast period.
-
Among 7MM, the United States had the highest prevalent cases of Molybdenum cofactor deficiency, with 124 cases in 2021, which was equivalent to 51% of total prevalent cases in 7MM.
-
Among the European countries, France had the highest prevalent population of Molybdenum cofactor deficiency with 24 cases, followed by Germany and the UK.
-
As per the gender-based epidemiology assessment, the MoCoD-A affects both genders equally.
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market
According to the DelveInsight analysis, the United States accounted for the highest market size, with more than 90% of the market share of MoCoD-A as compared to EU5 and Japan in the year 2021 due to the launch of a new therapy (Nulibry) in the US.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted MoCoD-A market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the MoCoD-A market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology Segmentation
-
Total Prevalent cases of MoCoD
-
Total Type-specific Diagnosed Prevalent cases of MoCoD
-
Total Diagnosed Prevalent Population of MoCoD
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the MoCoD-A Market or expected to get launched during the study period. The analysis covers Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the MoCoD-A Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Development
In the year 2021, the US FDA approved the first pharmacotherapy, Nulibry (fosdenopterin), for the treatment of patients affected with MoCoD type A. It is a substrate replacement therapy that provides an exogenous source of cPMP and is effective at treating MoCoD type A only.
Learn How Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/molybdenum-cofactor-deficiency-type-a-mocod-a-market
Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Therapeutics Analysis
Bridge Biopharma is the leading player in the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Therapeutics market.
On September 20, 2022, BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio) and Sentynl Therapeutics, Inc. (owned by Zydus Lifesciences Ltd.), announced the European Commission (EC) had granted marketing authorization for NULIBRY® (fosdenopterin), for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Earlier in 2021, Bridge Biopharma’s Nulibry, approved by the US FDA, is the first therapy to reduce mortality risk in patients with MoCoD Type A.
Molybdenum cofactor deficiency type A (MoCoD-A) market dynamics are anticipated to change in the coming years due approval of Nulibry (fosdenopterin).
The therapies for MoCoD are limited, which offers other pharma companies an opportunity to capture the market by scaling up R&D activities and producing novel treatments.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –
https://www.delveinsight.com/sample-request/molybdenum-cofactor-deficiency-type-a-mocod-a-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Competitive Intelligence Analysis
4. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Overview at a Glance
5. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Disease Background and Overview
6. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Patient Journey
7. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology and Patient Population (In US, EU5, and Japan)
8. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment Algorithm, Current Treatment, and Medical Practices
9. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Unmet Needs
10. Key Endpoints of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment
11. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Marketed Products
12. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Emerging Drugs and Latest Therapeutic Advances
13. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Seven Major Market Analysis
14. Attribute Analysis
15. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Outlook (In US, EU5, and Japan)
16. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Access and Reimbursement Overview
17. KOL Views on the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market
18. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Drivers
19. Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/molybdenum-cofactor-deficiency-type-a-mocod-a-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Tenosynovial Giant Cell Tumors (TSGCTs) Market
“Tenosynovial Giant Cell Tumors (TSGCTs) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
